Viking Therapeutics (1VT) Stock Forecast & Price Target

Compare

67 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1VT Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Viking

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1VT Stock 12 Month Forecast

Average Price Target

€83.97

▲(215.31%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is €83.97 with a high forecast of €107.50 and a low forecast of €60.20. The average price target represents a 215.31% change from the last price of €26.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","108":"€108","42.75":"€42.8","64.5":"€64.5","86.25":"€86.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.49627375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.9674893516,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€83.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.1979133,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€60.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,42.75,64.5,86.25,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.005,28.581251826923076,35.157503653846156,41.73375548076923,48.31000730769231,54.886259134615386,61.46251096153847,68.03876278846154,74.61501461538462,81.1912664423077,87.76751826923078,94.34377009615385,100.92002192307693,{"y":107.49627375,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.005,26.77134533473846,31.537690669476923,36.304036004215384,41.070381338953844,45.836726673692304,50.60307200843077,55.36941734316923,60.13576267790769,64.90210801264615,69.66845334738461,74.43479868212307,79.20114401686153,{"y":83.9674893516,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.005,24.94291640769231,27.880832815384615,30.81874922307692,33.756665630769234,36.69458203846154,39.632498446153846,42.57041485384616,45.50833126153846,48.44624766923077,51.38416407692308,54.322080484615384,57.2599968923077,{"y":60.1979133,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.34,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.005,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€107.50

Average Price Target€83.97

Lowest Price Target€60.20

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph PantginisH.C. Wainwright

H.C. Wainwright

€87.72

Buy

229.39%

Upside

Reiterated

06/30/25

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/26/25

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

George FarmerScotiabank

Scotiabank

€87.72

Buy

229.39%

Upside

Reiterated

06/26/25

Scotiabank Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Thomas SmithLeerink Partners

Leerink Partners

€101.48

Buy

281.06%

Upside

Reiterated

06/25/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

06/25/25

Viking Therapeutics' VK2735: A Promising Disruptor in the Obesity Market with Strategic Phase III Trials and Market Appeal

Justin ZelinBTIG

BTIG

€107.5

Buy

303.67%

Upside

Reiterated

06/25/25

BTIG 'encouraged' by Viking execution, progress in obesity franchiseBTIG 'encouraged' by Viking execution, progress in obesity franchise

Michael UlzMorgan Stanley

Morgan Stanley

€87.72

Buy

229.39%

Upside

Reiterated

06/25/25

Viking Therapeutics (VKTX) Receives a Buy from Morgan Stanley

Biren AminPiper Sandler

Piper Sandler

€61.06

Buy

129.28%

Upside

Reiterated

06/16/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

€89.44

Buy

235.85%

Upside

Initiated

04/28/25

Cantor Fitzgerald starts Viking Therapeutic (VKTX) at OverweightCantor Fitzgerald analyst Steven Seedhouse initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Overweight rating and a price target of $104.00.

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

€81.7

Buy

206.79%

Upside

Reiterated

04/24/25

Analysts Conflicted on These Healthcare Names: Qiagen (NYSE: QGEN) and Viking Therapeutics (NASDAQ: VKTX)

Mayank MamtaniB.Riley Financial

B.Riley Financial

€82.56→€73.1

Buy

174.49%

Upside

Reiterated

04/24/25

Viking Therapeutics price target lowered to $85 from $96 at B. RileyViking Therapeutics price target lowered to $85 from $96 at B. Riley

Naz RahmanMaxim Group

Maxim Group

€60.2

Buy

126.05%

Upside

Reiterated

04/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay OlsonOppenheimer

Oppenheimer

€141.04→€86

Buy

222.93%

Upside

Reiterated

04/23/25

Viking Therapeutic (VKTX) PT Lowered to $100 at OppenheimerOppenheimer analyst Jay Olson lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $100.00 (from $164.00) while maintaining a Outperform rating.

Richard Law CFAGoldman Sachs

Goldman Sachs

€25.8

Hold

-3.12%

Downside

Initiated

04/08/25

Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges

Hardik ParikhJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

03/11/25

Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph PantginisH.C. Wainwright

H.C. Wainwright

€87.72

Buy

229.39%

Upside

Reiterated

06/30/25

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/26/25

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

George FarmerScotiabank

Scotiabank

€87.72

Buy

229.39%

Upside

Reiterated

06/26/25

Scotiabank Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Thomas SmithLeerink Partners

Leerink Partners

€101.48

Buy

281.06%

Upside

Reiterated

06/25/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

06/25/25

Viking Therapeutics' VK2735: A Promising Disruptor in the Obesity Market with Strategic Phase III Trials and Market Appeal

Justin ZelinBTIG

BTIG

€107.5

Buy

303.67%

Upside

Reiterated

06/25/25

BTIG 'encouraged' by Viking execution, progress in obesity franchiseBTIG 'encouraged' by Viking execution, progress in obesity franchise

Michael UlzMorgan Stanley

Morgan Stanley

€87.72

Buy

229.39%

Upside

Reiterated

06/25/25

Viking Therapeutics (VKTX) Receives a Buy from Morgan Stanley

Biren AminPiper Sandler

Piper Sandler

€61.06

Buy

129.28%

Upside

Reiterated

06/16/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

€89.44

Buy

235.85%

Upside

Initiated

04/28/25

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

€81.7

Buy

206.79%

Upside

Reiterated

04/24/25

Analysts Conflicted on These Healthcare Names: Qiagen (NYSE: QGEN) and Viking Therapeutics (NASDAQ: VKTX)

Mayank MamtaniB.Riley Financial

B.Riley Financial

€82.56→€73.1

Buy

174.49%

Upside

Reiterated

04/24/25

Viking Therapeutics price target lowered to $85 from $96 at B. RileyViking Therapeutics price target lowered to $85 from $96 at B. Riley

Naz RahmanMaxim Group

Maxim Group

€60.2

Buy

126.05%

Upside

Reiterated

04/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay OlsonOppenheimer

Oppenheimer

€141.04→€86

Buy

222.93%

Upside

Reiterated

04/23/25

Richard Law CFAGoldman Sachs

Goldman Sachs

€25.8

Hold

-3.12%

Downside

Initiated

04/08/25

Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges

Hardik ParikhJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

03/11/25

Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+14.09%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +14.09% per trade.

3 Months

xxx

Success Rate

13/23 ratings generated profit

Average Return

+34.11%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +34.11% per trade.

1 Year

Naz RahmanMaxim Group

Success Rate

13/20 ratings generated profit

Average Return

+159.71%

reiterated a buy rating 3 months ago

Copying Naz Rahman's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +159.71% per trade.

2 Years

xxx

Success Rate

14/20 ratings generated profit

Average Return

+238.14%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +238.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1VT Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1VT has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1VT average Analyst price target in the past 3 months is 83.97.

Each month's total comprises the sum of three months' worth of ratings.

1VT Financial Forecast

1VT Earnings Forecast

Next quarter’s earnings estimate for 1VT is -€0.38 with a range of -€0.47 to -€0.26. The previous quarter’s EPS was -€0.35. 1VT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year 1VT has Outperformed its overall industry.

No data currently available

1VT Sales Forecast

Next quarter’s sales forecast for 1VT is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1VT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.00% of the time in the same period. In the last calendar year 1VT has Preformed in-line its overall industry.

1VT Stock Forecast FAQ

What is DE:1VT’s average 12-month price target, according to analysts?

Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 83.97.

What is DE:1VT’s upside potential, based on the analysts’ average price target?

Viking Therapeutics has 215.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Viking Therapeutics a Buy, Sell or Hold?

Viking Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Viking Therapeutics’s share price target?

The average share price target for Viking Therapeutics is 83.97. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €107.50 ,and the lowest forecast is €60.20. The average share price target represents 215.31% Increase from the current price of €26.63.

What do analysts say about Viking Therapeutics?

Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Viking Therapeutics?

To buy shares of DE:1VT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viking Therapeutics (1VT) Stock Forecast & Price Target

1VT Analyst Ratings

1VT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viking Therapeutics

1VT Analyst Recommendation Trends

1VT Financial Forecast

1VT Earnings Forecast

1VT Sales Forecast

1VT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts